Stevanato Group Unveils New Plant in Cisterna di Latina for the Production of Pre-Sterilized EZ-fill® Syringes and Cartridges
2024年5月30日 - 6:00PM
ビジネスワイヤ(英語)
Cisterna’s site is the first to implement premium solutions
outside the Group’s headquarters in Piombino Dese to meet the
growing demand for biopharmaceuticals, such as GLP-1s in
Europe.
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider
of drug containment, drug delivery, and diagnostic solutions to the
pharmaceutical, biotechnology and life science industries, today
announced the inauguration of its Cisterna di Latina plant.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240530371429/en/
External sight of the new Stevanato
Group's plant in Cisterna di Latina, Italy. (Photo: Business
Wire)
Located just a few kilometers from the Group's first historic
plant in Latina, the new site covers an area of 65,000 square
meters and employs around 200 people. The facility started
commercial production in Q4 2023 and houses advanced production
lines developed by Stevanato Group for the production of EZ-fill®
pre-sterilized syringes with the aim of responding to the modern
challenges of the European market, constantly growing in
biopharmaceuticals, such as GLP-1s. Furthermore, the Company is
planning to implement production with EZ-fill® pre-sterilized
cartridges between 2025 and 2026 as the site becomes fully
operational.
Franco Stevanato, Executive Chairman and CEO of Stevanato Group
said: “We are proud to have reached this new milestone, which will
allow us to strategically expand in one of the main pharmaceutical
hubs in our country. With the new plant in Cisterna di Latina, we
are increasing production capacity, helping to reinforce the supply
chain for Europe and furthering our commitment to customers, who
increasingly need high-quality drug containment systems, such as
our high-value solutions.”
Stevanato Group has been in the Lazio pharmaceutical district
since 1993, through its first plant at Tor Tre Ponti in Latina,
which is still in operation today with around 200 employees and is
dedicated to manufacturing bulk drug containment products. The
plant in Cisterna di Latina represents one of Stevanato Group's
most significant investments in the last five years. The Cisterna
site is the first of the Group to have implemented high-value
solutions production outside the Company’s headquarters in Piombino
Dese. The next one will be in Fishers, Indiana, U.S.
The Cisterna di Latina facility will support global
biopharmaceutical partners and customers with an integrated product
and service offering, aiming at optimizing the supply chain,
reducing overall risk, and improving time to market. The high-value
pre-sterilized solutions produced at the site will be ready for
filling, enabling customers to outsource some of the primary
packaging processing steps and focus exclusively on their core
business.
“Technological advances and continuous research are leading our
customers to develop more cutting-edge specialized treatments and
patient care. For this reason, it is essential to have effective
and safe drug containment systems, such as our high-value
solutions. By strengthening our presence in Latina, we are ready to
respond to this need with the aim of improving the quality of life
of patients,” concluded Franco Stevanato.
Forward-Looking Statements
This press release may include forward-looking statements. The
words “growing,” “is planning,” “will allow,” “will be,” “aiming,”
“will,” and similar expressions (or their negative) identify
certain of these forward-looking statements. These forward-looking
statements are statements regarding the Company's intentions,
beliefs or current expectations concerning, among other things, the
investments the Company expects to make, the expansion of
manufacturing capacity, business strategies, the Company’s capacity
to meet future market demands, and results of operations. The
forward-looking statements in this press release are based on
numerous assumptions regarding the Company’s present and future
business strategies and the environment in which the Company will
operate in the future. Forward-looking statements involve inherent
known and unknown risks, uncertainties and contingencies because
they relate to events and depend on circumstances that may or may
not occur in the future and may cause the actual results,
performance or achievements of the Company to be materially
different from those expressed or implied by such forward looking
statements. Many of these risks and uncertainties relate to factors
that are beyond the Company's ability to control or estimate
precisely, such as future market conditions, currency fluctuations,
the behavior of other market participants, the actions of
regulators and other factors such as the Company's ability to
continue to obtain financing to meet its liquidity needs, changes
in the political, social and regulatory framework in which the
Company operates or in economic or technological trends or
conditions. Readers should therefore not place undue reliance on
these statements, particularly not in connection with any contract
or investment decision. Except as required by law, the company
assumes no obligation to update any such forward-looking
statements.
About Stevanato Group
Founded in 1949, Stevanato Group is a leading global provider of
drug containment, drug delivery and diagnostic solutions to the
pharmaceutical, biotechnology and life sciences industries. The
Group delivers an integrated, end-to-end portfolio of products,
processes and services that address customer needs across the
entire drug life cycle at each of the development, clinical and
commercial stages. Stevanato Group’s core capabilities in
scientific research and development, its commitment to technical
innovation and its engineering excellence are central to its
ability to offer value added solutions to clients. To learn more,
visit: www.stevanatogroup.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240530371429/en/
Media relations: media@stevanatogroup.com Investor
relations: Lisa Miles: lisa.miles@stevanatogroup.com Team
Lewis for Stevanato Group: Cassie Gonzales:
stevanatoUS@teamlewis.com Nicolò Marcon, Arianna Cusolito:
stevanatoita@teamlewis.com
Stevanato (NYSE:STVN)
過去 株価チャート
から 11 2024 まで 12 2024
Stevanato (NYSE:STVN)
過去 株価チャート
から 12 2023 まで 12 2024